Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$12.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $12 billion, its work is significant in addressing unmet medical needs in areas like depression and migraine treatment.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite the miss, the stock rose 8.31% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Axsome's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see how the company addresses its recent performance and future outlook.

Bull Case

If Axsome can demonstrate significant progress in its pipeline and better-than-expected financial metrics, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to profitability, it may face downward pressure on its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Axsome report regarding its drug development pipeline?

Investors will be looking for concrete updates on product candidates that could drive future revenue and market growth.

How does Axsome plan to address its recent earnings misses and improve profitability?

Management's strategy for overcoming past performance issues will be critical in shaping investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Axsome's potential for a turnaround given its recent product pipeline advancements, which could lead to a more favorable financial outlook than currently anticipated.

Supporting Evidence

The stock has historically reacted positively to minor earnings beats, suggesting that even small improvements can drive significant investor interest.

Options pricing indicates a high expected move, which could reflect underlying investor optimism not captured in consensus estimates.

Key Risk

If Axsome can demonstrate a clear path to profitability with its upcoming report, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Axsome's ability to turn around its financial performance and demonstrate progress in its drug development efforts.

Bull Confirmed If

A significant reduction in EPS loss, ideally moving towards break-even, would confirm the bull case.

Bear Confirmed If

Continued large EPS losses without a clear plan for improvement would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.4%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect notable volatility following the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.6% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming investor optimism about its pipeline.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors assess management's commentary on future growth prospects.

Miss

If the company misses expectations again, history suggests a decline of about 1.28%, reflecting ongoing concerns about its profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key drug candidates in the pipeline.
2Management's strategy for improving financial performance and reducing losses.
3Any new partnerships or collaborations that could enhance growth prospects.
4Insights into R&D spending and its impact on future product launches.
5Guidance on expected revenue growth for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite the miss, the stock rose 8.31% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Axsome's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see how the company addresses its recent performance and future outlook.

Bull Case

If Axsome can demonstrate significant progress in its pipeline and better-than-expected financial metrics, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to profitability, it may face downward pressure on its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Axsome report regarding its drug development pipeline?

Investors will be looking for concrete updates on product candidates that could drive future revenue and market growth.

How does Axsome plan to address its recent earnings misses and improve profitability?

Management's strategy for overcoming past performance issues will be critical in shaping investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The stock has historically reacted positively to minor earnings beats, suggesting that even small improvements can drive significant investor interest.

Options pricing indicates a high expected move, which could reflect underlying investor optimism not captured in consensus estimates.

Key Risk

If Axsome can demonstrate a clear path to profitability with its upcoming report, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Axsome's ability to turn around its financial performance and demonstrate progress in its drug development efforts.

Bull Confirmed If

A significant reduction in EPS loss, ideally moving towards break-even, would confirm the bull case.

Bear Confirmed If

Continued large EPS losses without a clear plan for improvement would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.4%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect notable volatility following the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming investor optimism about its pipeline.

In-Line / Cautious

An in-line report may lead to a muted reaction, as investors assess management's commentary on future growth prospects.

Miss

If the company misses expectations again, history suggests a decline of about 1.28%, reflecting ongoing concerns about its profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key drug candidates in the pipeline.
2Management's strategy for improving financial performance and reducing losses.
3Any new partnerships or collaborations that could enhance growth prospects.
4Insights into R&D spending and its impact on future product launches.
5Guidance on expected revenue growth for the upcoming quarters.